Shaping IR Spectroscopy into a Powerful Tool for Biopharma Characterizations
In this peer-reviewed article, the authors present a series of experimental studies showcasing the performance of MMS in secondary-structure biopharma characterization and compare it with conventional FTIR data.
molekuul.be/Stock.adobe.com
Microfluidic modulation spectroscopy (MMS) is a novel automated infrared spectroscopic technique with high sensitivity and repeatability. Here, the authors present a series of experimental studies showcasing the performance of MMS in the secondary structure characterization of biopharmaceutical products and compare the MMS results with the conventional Fourier transform infrared data.
Click
herefor a PDF of the article.
Peer-reviewed
Submitted: Dec. 9, 2019
Accepted: March 9, 2020
About the authors
Dipanwita Batabyal*, dbatabya@amgen.com, is scientist at Attribute Sciences-Higher Order Structure Group, Amgen, and Mats Wikström*, matsw@amgen.com, is principal scientist at Higher Order Structure, BR&C, Attribute Sciences, Amgen. Libo Wang is principal application scientist and Jeffrey Zonderman is chief commercial officer at RedShift Bioanalytics.
*To whom correspondence should be addressed.
Article Details
BioPharm International
Vol. 33, No. 5
May 2020
Pages: 42–47
Citation
When referring to this article, please cite it as F. Mirasol, “Shaping IR Spectroscopy into a Powerful Tool for Biopharma Characterizations,” BioPharm International 33 (5) 2020.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
